LGL Group (NYSEAMERICAN:LGL) Posts Earnings Results, Misses Expectations By $0.07 EPS

LGL Group (NYSEAMERICAN:LGL) announced its earnings results on Friday. The industrial products company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.07), FiscalAI reports. The firm had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.80 million. LGL Group had a net margin of 1.66% and a return on equity of 0.16%.

LGL Group Trading Down 1.6%

Shares of LGL Group stock traded down $0.12 on Friday, reaching $7.43. 6,750 shares of the stock were exchanged, compared to its average volume of 13,059. The firm has a market capitalization of $48.59 million, a PE ratio of 743.74 and a beta of 0.32. LGL Group has a 1-year low of $5.45 and a 1-year high of $7.57. The business has a fifty day moving average price of $6.95 and a two-hundred day moving average price of $7.06.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded LGL Group to a “hold” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold”.

Institutional Investors Weigh In On LGL Group

A hedge fund recently bought a new position in LGL Group stock. Citadel Advisors LLC bought a new position in shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned 0.25% of LGL Group at the end of the most recent quarter. 30.28% of the stock is owned by hedge funds and other institutional investors.

LGL Group Company Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.